William Blair Weighs in on Envista’s Q1 Earnings (NYSE:NVST)

Envista Holdings Co. (NYSE:NVST) – William Blair cut their Q1 2025 earnings per share (EPS) estimates for Envista in a report issued on Thursday, February 6th. William Blair analyst B. Vazquez now expects that the company will post earnings per share of $0.21 for the quarter, down from their prior estimate of $0.27. The consensus estimate for Envista’s current full-year earnings is $1.06 per share. William Blair also issued estimates for Envista’s Q2 2025 earnings at $0.22 EPS, Q3 2025 earnings at $0.21 EPS, FY2025 earnings at $0.97 EPS and FY2026 earnings at $1.06 EPS.

Envista (NYSE:NVST) last posted its earnings results on Wednesday, February 5th. The company reported $0.24 EPS for the quarter, beating analysts’ consensus estimates of $0.23 by $0.01. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%.

A number of other equities research analysts also recently commented on NVST. Needham & Company LLC restated a “hold” rating on shares of Envista in a research report on Thursday, February 6th. Leerink Partnrs upgraded Envista from a “strong sell” rating to a “hold” rating in a research report on Thursday, October 31st. Mizuho began coverage on Envista in a research note on Wednesday, December 4th. They issued an “underperform” rating and a $20.00 price objective for the company. Wells Fargo & Company lifted their price objective on Envista from $20.00 to $21.00 and gave the company an “equal weight” rating in a research note on Thursday, February 6th. Finally, Leerink Partners raised Envista from an “underperform” rating to a “market perform” rating and lifted their price objective for the company from $16.00 to $23.00 in a research note on Thursday, October 31st. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, Envista has an average rating of “Hold” and a consensus price target of $20.21.

Envista Price Performance

NYSE:NVST opened at $21.24 on Monday. Envista has a 52 week low of $15.15 and a 52 week high of $23.06. The company has a quick ratio of 1.77, a current ratio of 2.04 and a debt-to-equity ratio of 0.44. The company has a market capitalization of $3.66 billion, a P/E ratio of -3.27, a P/E/G ratio of 2.06 and a beta of 1.34. The stock’s fifty day moving average is $19.94 and its two-hundred day moving average is $19.20.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Envista during the 3rd quarter worth about $31,000. GAMMA Investing LLC lifted its holdings in Envista by 69.8% during the 3rd quarter. GAMMA Investing LLC now owns 1,766 shares of the company’s stock worth $35,000 after buying an additional 726 shares during the last quarter. Huntington National Bank lifted its holdings in Envista by 97.8% during the 3rd quarter. Huntington National Bank now owns 1,919 shares of the company’s stock worth $38,000 after buying an additional 949 shares during the last quarter. Venturi Wealth Management LLC lifted its holdings in Envista by 528.4% during the 4th quarter. Venturi Wealth Management LLC now owns 1,948 shares of the company’s stock worth $38,000 after buying an additional 1,638 shares during the last quarter. Finally, Blue Trust Inc. lifted its holdings in Envista by 69.7% during the 3rd quarter. Blue Trust Inc. now owns 1,957 shares of the company’s stock worth $39,000 after buying an additional 804 shares during the last quarter.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.